SEC Tracker
Get the app

Intellia Therapeutics NTLA

Intellia Therapeutics reported a $127.49 million net loss for Q3 2026.

Form
10-Q
Filed
Importance
Notable
  1. Revenue: $7.16 million for the three months ended Sep 30, 2026
  2. Net loss: $127.49 million for the three months ended Sep 30, 2026
  3. Cash and equivalents: $156.1 million at Sep 30, 2026

Written from the 10-Q on EDGAR. AI can make mistakes. Check the filing.

Open in the appGet the appView on EDGAR

Get an email when Intellia Therapeutics files

Only major filings: results, leadership changes, listing notices and other major events, each with the plain-English summary when we have one or the key facts and the EDGAR link. Routine insider filings never email. Confirm once; unsubscribe in one click.

Similar companies

Companies of similar size in SIC 2835 and related industry codes: the same peer list as the financial tables.

  1. Geron GERN public float $861M, Jun 30, 2025
  2. Wave Life Sciences WVE public float $851M, Jun 30, 2025
  3. Cyanotech CYAN
  4. CorMedix CRMD public float $910M, Jun 30, 2025
  5. Ardelyx ARDX public float $924M, Jun 30, 2025

Data on this page was fetched . The filing on SEC.gov is the record.